EMA adopts open trial data policy to begin Jan. 1

Emily Mullin The European Medicines Agency adopted a new policy on Oct. 2 that requires drug companies to make public certain clinical data that predicate drug approvals. FierceBiotech ...

Report: Arbor Pharma goes on the block for $1B-plus

Damian Garde Private drugmaker Arbor Pharmaceuticals is looking for a buyer, according to Reuters, going on the market with a price tag that could exceed $ 1 billion. FierceBiotech ...

Catalyst Pharma to join parade of huge price hikes on old, cheap drugs

Tracy Staton Yet another drugmaker is taking a cheap drug and turning it into an FDA-approved brand–and adding an enormous premium along the way. Once again, the cost increase ...

IPO hopeful rEVO puts off its plans for a $75M debut

Damian Garde Massachusetts biotech rEVO Biolgoics is postponing its efforts to go public in a $ 75 million IPO. FierceBiotech News

Takeda back in court facing bladder cancer claims against Actos

Tracy Staton Lawyers in another Actos failure-to-warn trial claimed the company put profits ahead of patient safety, by keeping mum on study data that flagged links between the diabetes ...

FDA flags particle problems in latest Hospira warning letter

Tracy Staton Hospira's FDA woes have moved to Australia. The agency scolded the U.S.-based company in a warning letter based on an injectables plant inspection in late February ...

Allergan blueprints a big Texas expansion amid battle with spendthrift Valeant

Damian Garde Allergan has signed a lease for big chunk of office space in Texas, according to the Austin Business Journal, keeping quiet on its plans as it slashes jobs around the globe. FierceBiotech ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS